<?xml version="1.0" encoding="UTF-8"?>
<ref id="B54-viruses-12-00520">
 <label>54.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Lemckert</surname>
    <given-names>A.A.</given-names>
   </name>
   <name>
    <surname>Sumida</surname>
    <given-names>S.M.</given-names>
   </name>
   <name>
    <surname>Holterman</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Vogels</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Truitt</surname>
    <given-names>D.M.</given-names>
   </name>
   <name>
    <surname>Lynch</surname>
    <given-names>D.M.</given-names>
   </name>
   <name>
    <surname>Nanda</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Ewald</surname>
    <given-names>B.A.</given-names>
   </name>
   <name>
    <surname>Gorgone</surname>
    <given-names>D.A.</given-names>
   </name>
   <name>
    <surname>Lifton</surname>
    <given-names>M.A.</given-names>
   </name>
  </person-group>
  <article-title>Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity</article-title>
  <source>J. Virol.</source>
  <year>2005</year>
  <volume>79</volume>
  <fpage>9694</fpage>
  <lpage>9701</lpage>
  <pub-id pub-id-type="doi">10.1128/JVI.79.15.9694-9701.2005</pub-id>
  <pub-id pub-id-type="pmid">16014931</pub-id>
 </element-citation>
</ref>
